BioPharma Clinical Trials
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
Selinexor was granted orphan drug designation in MF by the U. S. Food and Drug Administration (FDA) in May 2022. Karyopharm is currently evaluating se...
November 02, 2022 | News
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
The IND application was submitted in partnership with Grand Pharmaceutical Group Limited (Grand Pharma), Telix's partner in the Greater China reg...
October 17, 2022 | News
Merck to Support Jacobio Pharma on Clinical Trial of JAB-21822 in Combination with Cetuximab
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer. Jacobio ...
October 13, 2022 | News
First patient treated in Clarity's therapeutic prostate cancer trial
Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT0...
October 10, 2022 | News
Australia's Paradigm Biopharmaceuticals reports positive early osteoarthritis drug trial results
Australian repurposing drug company Paradigm Biopharmaceuticals says positive clinical trial results for its osteoarthritis drug candidate indicate a poten...
October 07, 2022 | News
RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates
The Phase 1 study is an open-label, dose escalation study to evaluate the safety and immunogenicity of RVM-V001 in approximately 54 healthy adults in ...
September 23, 2022 | News
Menarini and SciClone to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections
Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumo...
September 21, 2022 | News
Qurient Announces Collaboration Agreement with MSD
Q901 is a novel highly selective CDK7 inhibitor Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors ...
September 19, 2022 | News
Merck announced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (formerly known as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in patients
First randomized trial in decades to show significant improvement in overall survival in patients with LA SCCHN, reinforcing the transformative potential...
September 14, 2022 | News
Cytel expansion unlocks innovative clinical trial capabilities for APAC biopharma sector
This enables biotech and biopharma companies in APAC to have easier access to Cytel’s established biometrics and advanced statistical solutions. For ...
September 07, 2022 | News
Jacobio Completes First Patient Dosage of CD73 mAb JAB-BX102 in China
This is a phase I/IIa multi-center, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of anti-tumo...
September 05, 2022 | News
EpiEndo Commences LPS Challenge Trial for Lead Candidate EP395
EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chro...
September 01, 2022 | News
Nuance Pharma Announces Clearance of IND Application for Ensifentrine Pivotal Clinical Trials for COPD in China
Ensifentrine is a first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") combining bronchodilator and anti-inflam...
August 21, 2022 | News
Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company developing novel drugs for cancer, fibrosis and inflammation, announ...
August 17, 2022 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
